| To: tuck who wrote (2545) | 7/1/2006 8:27:54 PM | | From: Ian@SI | | | | Hi Tuck,
1. I see you caught my disease. ...the stock had been whacked recently on loosing some sort of ground to Insmed... Thank god that a well educated, literate sort can also suffer a momentary lapse.
2. I know of at least one other trade of yours that's going well so far. Yes, the NKTR play caught me by surprise. I really wasn't expecting much to happen before the end of July. It does make me wonder if I should just take the offering and hope to get it again prior to month end???
I haven't any clue whether the last couple days is the start of something serious; or, if it was just some technical Month/Quarter/Half move. |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Ian@SI who wrote (2548) | 7/1/2006 9:44:58 PM | | From: Robohogs | | | | I feel like an idiot myself - took losses in DOVP/NBIX complex, did not sell the expensive calls in SEPR to cover and only picked up small trading stakes in NKTR/ARNA. ARNA is up as much as NKTR after being down 8% right before FED moved - had thought about adding more but could not do so when Rick was ranting about the shorts as I was worried about the FED reaction. How stupid can one believe. Nice trades guys!
Ian - you are the only other NKTR owner I have seen post. Most are dismissive of them as "me-too" and lifestyle. I personally do not care as I think the valuation disconnect between them and AMLN is too large. Economics an Exubera are not quite as good as Byetta (20% royalty with some mfg costs offsetting vs half of profits) but I think Exubera will be a quicker hitter than many think. Of course, I want to be out when the lung problems start.
Jon |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Robohogs who wrote (2549) | 7/1/2006 10:00:52 PM | | From: Ian@SI | | | | | As Tuck said, IF pt compliance improves with Exubera, then it will be prescribed. I don't understand the needle phobia thing, but then again, I don't stick myself multiple times a day. |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: nigel bates | 7/5/2006 10:43:41 AM | | | | | | ARDM 30% on partnership 'restructuring' -
HAYWARD, CA--(MARKET WIRE)--Jul 5, 2006 -- Aradigm Corporation (Nasdaq:ARDM - News) today announced the execution of an agreement further developing the strategic partnership with Novo Nordisk. The agreement is designed to strengthen Novo Nordisk's patent position within the area of inhaled insulin as related products progress towards commercialization and has resulted in a non-dilutive cash infusion to Aradigm of $27.5 million. The Novo Nordisk inhaled insulin program is currently in Phase 3 clinical trials. This agreement is comprised of an intellectual property assignment, a royalty prepayment and an eight-year promissory note. The promissory note is secured by the royalty payments on the AERx Diabetes Management System (iDMS) sold under the Aradigm license.
The key features to the restructuring and cash infusion include:
-- Aradigm's receipt of $12 million in exchange for transferring to Novo
Nordisk the ownership of a select number of patents that are especially
important for inhaled insulin. Aradigm will retain exclusive, royalty-free
control of these patents outside the field of glucose control and will
continue to be entitled to royalties in respect to any inhaled insulin
products marketed by Novo Nordisk.
-- The receipt by Aradigm of $8 million in exchange for a 100 basis point
or 1% reduction on its average royalty rate set forth by the commercialized
AERx iDMS product. This will result in Aradigm receiving royalty rates that
will rise to an average of 5% or higher by the fifth year after
commercialization.
-- Finally, Novo Nordisk has paid Aradigm $7.5 million in a 5%, eight-
year note that is payable in three equal payments commencing in six years,
and is secured by the royalty payments to Aradigm upon the
commercialization of the AERx iDMS product. |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: Ian@SI who wrote (2542) | 7/11/2006 2:36:06 PM | | From: scaram(o)uche | | | | Nah, I didn't catch anything at the end of the quarter. Did a little buying, but the only trading that I did was a couple of small winners to make up, in part, for losses held in the same issue.
Best, all!
Rick |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: DewDiligence_on_SI who wrote (2553) | 7/18/2006 3:35:52 PM | | From: tuck | | | | It's really been a while since there's been a legitimate posting here -- two weeks -- since I don't recall FRX quite making the cut in actuality. That's how tough this bear has been lately. Be that as it may, TRCA just took off, about 22%. Don't see any news since the patent ruling a couple of weeks ago. Can't say I understand the ins and outs of the INSM/TRCA dispute. I gather INSM's compound has a dosing advantage, but at least some of the IP battle seems to be going TRCA's way?
Whatever, it stands out on a day like today.
Cheers, Tuck |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: nigel bates who wrote (2556) | 7/19/2006 12:15:49 PM | | From: tuck | | | | >>ILMN nearly 20%.<<
On huge price cut on competing AFFX product:
SANTA CLARA, Calif. (AP) -- Shares of genetic analysis technology company Affymetrix Inc. slipped Wednesday following the company's move to reduce prices of a product used to test drug candidates.
The company said late Tuesday it is immediately cutting prices on its 500K SNP (single nucleotide polymorphisms) system to $250 and will offer the two-chip system as a single array by the end of the year. The company did not detail the product's original price, but UBS Investment Research analyst Derik De Bruin estimates it at around $750.
The company's stock slid $1.07, or 4.6 percent, to $22.28 on the Nasdaq in morning trading. It hit a new 52-week low earlier in the session, sliding to $22.02 before regaining some ground.
Analysts attribute the price-cutting move to growing competition from rival Illumina Inc. Illumina recently launched chip, the HumanHap550, which contains over 550,000 SNP on one chip, making it more powerful than Affymetrix's product, which contains 500,000.
Affymetrix said Tuesday it plans on releasing a system with 1 million SNP by the first quarter of 2007, with an expected price of $500.
While several analysts held their ratings for Affymetrix, some price targets were lowered on concerns over sales volume.
"We interpret Affymetrix's announcements as a sign that its genotyping business likely will not rebound until 2007," wrote Baird analyst Quintin J. Lai in a research report Wednesday.
Lai maintained a "Neutral" rating but cut his price target to $25 from $30, saying the price cut in its genotyping system is a "negative reflection on its current competitiveness" against Illumina's product.
UBS Investment Research analyst Derik De Bruin maintained his "Reduce" rating, but shaved his price target to $22 from $23, citing competition.
"Affymetrix has dominated the microarray arena, but execution problems have undercut investor confidence, calling into question (its) competitive position in the market outlook," he wrote in a report to investors.
While the price cutting move may help the company maintain its market share in the near-term, De Bruin said growth and margins could be constrained if it doesn't ramp up volumes.
Shares of Illumina surged $6.86, or 23.8 percent, to $35.71 on the Nasdaq in morning trading, eclipsing their previous 52-week high of $32.60 set July 6.<<
Cheers, Tuck (with another high five to George! If that's in his charity portfolio, look out.) |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
